BCM
ALXO icon

Bronte Capital Management’s ALX Oncology ALXO Stock Holding History

Bronte Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.5K Buy
+18,095
New +$32.4K ﹤0.01% 46

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Bronte Capital Management's ALXO Position: Q2 2026 in Review

Bronte Capital Management opened a new position in ALX Oncology (ALXO) in Q2 2026: 18,095 shares worth $37.5K. The stake represents ﹤0.01% of the portfolio and ranks #46 among its holdings.

94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Bronte Capital Management held 18,095 shares of ALX Oncology worth $37.5K as of Q2 2026.
  • ALX Oncology was a new Bronte Capital Management position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Bronte Capital Management's portfolio in Q2 2026, its #46 holding.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.